Novo Nordisk's Pipeline Reckoning: Paediatric Win Meets Prescription Slump Ahead of September 21 Capital Markets Day
Published on 09/10/2026 at 12:11 | Editorial boerse-global.de
Two announcements landed within days of each other this week, pulling Novo Nordisk's investment case in opposite directions. On one side sits a genuine clinical first: semaglutide hit its primary endpoint in the Phase 3 STEP Young trial, clearing a path into a paediatric obesity market that has until now been therapeutic virgin territory. On the other, the Danish drugmaker quietly wound down two more Phase 3 studies of ziltivekimab in heart failure — a retreat that removes a slice of the diversification story management has been building beyond semaglutide.
The market's reaction to the setback was counterintuitive. Rather than selling off, the stock added 1.1%, a move that suggests investors welcomed the clarity of a clean failure and the prospect of resources being redeployed elsewhere. Novo Nordisk had already alerted trial investigators the previous Friday that the two heart failure studies were being halted; an independent data monitoring committee, after reviewing interim results, saw no realistic chance of an outcome diverging from the earlier cardiovascular trial that had already missed. Reuters reported the disclosure on Monday. A third ziltivekimab study, this one in patients recovering from acute myocardial infarction, continues, with readouts expected in the first half of 2027.
A milestone in the youngest patients yet
The paediatric data carry more strategic weight. In STEP Young, semaglutide combined with lifestyle intervention produced a marked effect in children aged six to under twelve living with obesity. By week 68, 40.4% of treated children no longer met the criteria for an obesity diagnosis. In the placebo arm, that figure was zero. No new safety signals emerged.
For a company whose entire commercial architecture rests on the efficacy of GLP-1 agents, the result points toward a vast and previously untapped patient population. Whether regulators in the US or the European Medicines Agency widen the semaglutide label to cover younger children will determine how quickly that opportunity converts into revenue.
Prescriptions tell a less flattering story
Yet the stock has been unable to hold onto gains from positive product news. Since the German launch of the oral Wegovy tablet roughly a week ago — the first EU market to receive the pill — the shares have shed about 4.3%. That decline fits a broader pattern of weakening momentum. Over seven days the stock is down 5%, and over 30 days it has lost a little more than 5%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The drag traces back to prescription trends. Deutsche Bank Research reiterated a sell rating on 2 September with a price target of 265 Danish kroner. Analyst Emmanuel Papadakis pointed to weekly prescription data through 21 August showing a slowdown in new prescriptions for the company's core GLP-1 products — with one exception: the oral Wegovy formulation. Citi issued the same call on the same day, also citing IQVIA weekly prescription data and the same 265 kroner target. The one bright spot in an otherwise dimming prescription picture is precisely the product now rolling out in Germany.
Price action reflects the mixed signals. At a close of EUR 38.37, the stock sits roughly 30% below its 52-week high of EUR 54.86 set in January, though it remains about 27% above its early-March low. Year-to-date the shares are down 13%, and over twelve months the decline reaches 17%. The stock is trading around 6.2% below its 50-day moving average of EUR 41.34 — a sign that the near-term trend still points downward. An RSI of 39.6 does not signal extreme oversold conditions but does point to persistently weak momentum, consistent with annualised volatility of 40% that captures how nervously the market is pricing the company. A separate reading puts RSI at 42.5, leaving room for a re-rating higher without either overbought or oversold conditions being triggered.
The question that September 21 must answer
Whether Novo Nordisk can climb out of its current soft patch hinges on a single issue: can the company credibly fill the pipeline vacuum left by the ziltivekimab setback with new growth areas such as the paediatric obesity indication and the Wegovy tablet? Capital markets value pharmaceutical companies on the expected future earnings power of their pipelines — a failed compound matters only insofar as other candidates can compensate for it.
The capital markets day in London on 21 September is the next scheduled event at which investors can expect a consolidated assessment of pipeline setbacks and opportunities. Management intends to present strategy, research pipeline, operational setup and business development. For a company navigating between a paediatric breakthrough, a discontinued heart failure programme and declining prescriptions for established products, the occasion is more than routine.
Where the scenarios diverge
Should the STEP Young data hold up in further analyses and should the US Food and Drug Administration or the European Medicines Agency extend semaglutide's indication to younger children, Novo Nordisk gains access to an additional, previously unexploited market segment. Combined with the ongoing rollout of the Wegovy tablet in more countries, the company could defend its position in the GLP-1 market despite intensifying competition. In that scenario, the capital markets day would be read as a turning point, shifting focus away from the failed heart failure studies and toward new growth drivers.
Sceptics, however, point to a structural slowdown in the core business. If the prescription trend persists, even positive paediatric news would not solve the underlying growth problem. On top of that, the final outcome of the third ziltivekimab study remains open, and another setback in the first half of 2027 cannot be ruled out.
As long as prescription dynamics for established GLP-1 products stay weak, the shares are likely to remain within their recent trading range, even if individual pipeline announcements such as the STEP Young data provide short-term lift. A turn in the trend — whether through stabilising new prescriptions or concrete regulatory progress on the paediatric indication — would open room for a more durable recovery. Until then, the stock remains a weighing of an intact but bruised core business against promising yet unproven new growth fields, with the 21 September capital markets day serving as the first real test of whether management can fuse these divergent signals into a convincing growth narrative.
Ad
Novo Nordisk Stock: New Analysis - 10 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
